This case illustrates that in severe EGFR-TKI–associated ILD, high-dose corticosteroid regimens combined with adjunctive immunomodulatory therapy may confer clinical benefit, offering a valuable reference for refining future treatment protocols, though further studies are needed to validate their efficacy. This evidence concerns the gene EGFR and interstitial lung disease.